INTRODUCTION
Epigenetic factors offer important new targets for cancer therapy given their crucial role in the regulation of major cancer-relevant transcriptional programs and their potential reversibility (1) . Significant effort has been directed towards identifying key epigenetic regulators in certain cancer contexts and elucidating the specific mechanisms, cell biological processes and surrogate transcriptional networks governed by these factors. However, we have limited understanding of the roles of epigenetic regulators in melanoma progression.
Melanoma is an aggressive cancer with escalating incidence worldwide (2) .
Melanoma deaths stem primarily from widespread metastatic disease (2) , though genetic determinants and molecular mechanisms driving this disease remain poorly understood. Recent integrated genomic and functional screening efforts have identified pro-invasive determinants of melanoma metastasis with potential prognostic significance (3) . The list of 18 prognostic determinants that emerged from this screen was identified based on evidence of pro-invasive and oncogenic capabilities in vitro and in vivo, in addition to genomic and expression alterations in human melanomas. On this list of 18, four were known epigenetic regulators: ASF1B (4), HMGB1 (5), RNF2 (6) and UCHL5 (7) .
In this study, we focus on RNF2, a component of the polycomb repressor complex-1. RNF2 catalyzes mono-ubiquitination of lysine 119 of histone H2A (H2AK119Ub) (6, 8) and is overexpressed in gastrointestinal tumors, lymphomas and pancreatic cancers (9, 10). However, it is not known whether RNF2 overexpression is 
RESULTS

RNF2 is a prognostic metastasis oncogene in human melanoma
RNF2 was previously identified as a candidate pro-metastasis oncogene (3).
Here, we set out to validate its pro-metastatic and oncogenic activities and discern functional mechanisms. Metastatic function was assessed in multiple melanoma cell models, including two primary immortalized human melanocyte lines constitutively expressing TERT, p53 DD , CDK4 R24C and either BRAF V600E or NRAS G12D mutant proteins To substantiate the relevance of RNF2 in human melanoma, we verified that RNF2 expression correlates with disease progression at the mRNA and protein levels.
Specifically, as summarized in Supplementary Figure 3A , RNF2 mRNA expression was elevated in primary melanoma tissue compared to skin and nevi (13) and, in an independent cohort, was significantly higher in metastatic lesions when compared to localized primary tumors (Supplementary Figure 3B) 154 cases, we found that, indeed, elevated RNF2 levels were associated with poorer overall survival (log-rank P value < 0.0039, Figure 2B ), confirming the prognostic significance of RNF2 in melanoma.
RNF2 has both catalytic dependent and independent activities
Given RNF2's known transcriptional repressor and catalytic activities, we sought to determine whether RNF2's catalytic activity is required for its pro-invasion and protumorigenic phenotypes. Mutant forms of RNF2: RNF2 I53S and RNF2
R70C
, shown previously to lack catalytic activity (15, 16) , were engineered. We found that as expected, these mutants showed diminished invasion and metastasis activity compared to RNF2 WT ( Figure 1A -B and Supplementary Figures 1A-B) . However, to our surprise, both RNF2 I53S and RNF2 R70C mutants retained the capacity to enhance proliferation and anchorage independent growth in vitro, and tumorigenicity in vivo, at levels comparable Figure 2C and Supplementary Figure 3E) .
To address the possible confounding effect of endogenous RNF2 expression in the above study, we engineered a mouse line bearing a conditional RNF2 knockout allele with LoxP sites flanking exon 2 (Supplementary Figure 3F) , where Cre-mediated recombination results in loss of RNF2 protein expression ( Figure 2D deficiency was associated with significant reduction in tumor burden at 14 weeks and improved survival ( Figure 2E and Supplementary Figure 3G ).
Using this genetic system in which RNF2 can be rendered homozygous null, we re-assessed the differential requirement of RNF2 catalytic activity in cellular proliferation and invasion. Specifically, melanoma cells derived from iBIP-RNF2 L/L animals were transduced with lentivirus encoding RNF2 WT and RNF2 I53S ( Figure 2D ) and assayed for proliferation and invasion along with the levels of H2AK119 mark. Consistent with studies above, RNF2 catalytic activity was dispensable for proliferation enhancement yet required for invasion ( Figure 2F-H) . Taken together, these in vitro and in vivo functional assays suggested that, unlike its metastatic function, RNF2's oncogenic potential is not dependent on its catalytic activity.
RNF2 promotes TGFβ signaling via down-regulation of LTBP2
To explore the mechanistic basis of RNF2's cancer relevant activities, transcriptome profiling (Supplementary Figure 4A) and ChIP-seq 
RNF2 promotes tumorigenesis through up-regulation of CyclinD2
As noted above, many genes proximal to RNF2 occupancy sites in HMEL-
RNF2
WT melanocytes showed increased expression ( Figure 3A) . Indeed, the most 
Pre-existing chromatin promoter states determine the genes activated by RNF2
Next we sought to understand how RNF2 might promote gene activation contrary to its known role in gene repression. We considered the possibility that the promoter, which is repressed when RNF2 is expressed, showed enrichment of active promoter states (States 1, 2) and active promoter marks (H3K4me3, H3K9Ac) as well as enhancer states (States 7,8,9) and enhancer (H3K27Ac) marks ( Figure 5D ). These data suggest that genes activated by RNF2 may be marked, or poised, by repressionassociated mark H3K27me3 prior to RNF2-mediated activation and gain of histone acetylation marks.
RNF2 recruits UTX and p300 to the CCND2 promoter.
Recently, MLL2, UTX and p400 were identified as RNF2 associated proteins in mouse ES cells, which co-migrate on a sucrose gradient separately from RNF2-containing PRC1 components (25). This observation suggests that a fraction of RNF2 molecules may exist in an activating complex with MLL2, UTX or p400. Therefore, we hypothesized that a sub-fraction of RNF2 may preferentially recruit activating factors to the H3K27me3 containing poised promoters. To investigate this, we first tested whether RNF2 overexpression led to H3K27me3 loss on activated promoters. Indeed, RNF2 overexpression led to loss of H3K27me3 occupancy as well as gain of histone acetylation marks (H3K9Ac, H3K27Ac and H4TetraAc) on CCND2 promoter ( Figure 6A and Figure 4B ). These histone modification events upon RNF2 overexpression were consistent with RNF2's suggested interaction with UTX, an H3K27 demethylase and p300, a histone acetyltransferase (25). Indeed, ChIP-qPCR showed that UTX and p300 were enriched on CCND2 promoter after RNF2 overexpression ( Figure 6B ). Consistent with these observations, we noted interactions between RNF2 and UTX by coimmunoprecipitation in HMEL-BRAF   V600E   -RNF2 WT cells ( Figure 6C ). Finally, we tested whether UTX and p300 recruitment by RNF2 had any impact on transcriptional activation of CCND2 promoter. Downregulation of UTX or p300 individually by shRNAs significantly reduced CCND2 expression in RNF2 overexpressing cells but not in control Figure 6D ). Together these observations suggest that recruitment of UTX and p300 to CCND2 promoter by RNF2 is critical for creating activating chromatin environment as well as transcriptional activation.
MEK mediated phosphorylation of RNF2
To understand how RNF2 might act as both an activator and a repressor in the same cell, we asked whether a particular modified form of RNF2 is important for gene activation. It was previously shown that RNF2 is phosphorylated in a MEK dependent manner and this phosphorylation may be associated with histone acetylation events (26). Since RNF2 overexpression was studied in the context of activated MAPK signaling (due to BRAF V600E mutation), which is known to activate MEK, we asked whether phosphorylation of RNF2 by MEK may be important for its role in gene activation in the context of melanoma. We first verified that MEK1 is indeed able to phosphorylate RNF2 using an in vitro kinase assay ( Figure 7A ). Moreover, serine 41
(26) to alanine mutant derivative of RNF2 showed significantly reduced phosphorylation compared to wild type whereas S168A and S208A mutant derivatives were phosphorylated to the same extent as wild type RNF2. Figure   7B ). Consistently, RNF2 induced H3K27me3 demethylation, H3K27Ac accumulation and UTX/p300 recruitment at the CCND2 promoter, which were abrogated by MEK inhibition in RNF2 WT overexpressing cells ( Figure 7C ). In parallel, S41A mutant was inefficient in promoting H3K27me3 demethylation, inducing H3K27Ac and UTX/p300 recruitment ( Figure 7C ). Consistently, MEK inhibition and S41A mutant drastically reduced interaction between RNF2 and UTX ( Figure 7D ). Finally, we showed that MEK inhibition
Research. 
DISCUSSION
In this study, we elucidated distinct molecular mechanisms by which RNF2 regulates proliferation and invasion, highlighting the complex and multi-faceted action of epigenetic regulators. Molecularly, the intersection of RNF2 chromatin binding and gene expression analyses identified RNF2-occupied repressed and active promoters.
Biologically, a series of reinforcing functional assays utilizing both somatic and genetically engineered germline model systems demonstrated that RNF2's catalytic activity is dispensable for CCND2 activation, which drives proliferation, but is required for suppression of LTBP2 and activation of TGFβ signaling for invasion and metastasis.
Although it has been suggested that RNF2 may promote gene repression by chromatin compaction independently of its catalytic activity (27), this is the first report of RNF2's role in gene activation independent of its E3 ubiquitin ligase activity. In this regard, we find that ~53% of genes with RNF2-occupied promoters were upregulated in An important question is whether pro-metastatic and pro-tumorigenic activities of RNF2 are completely independent of each other. Although we provide evidence that proinvasive/metastatic function is dependent on RNF2's catalytic activity and protumorigenic role is independent of it, our data do not completely rule out the possibility that RNF2's role in proliferation also contributes to its pro-metastatic phenotype.
Taken together, our findings provide strong evidence that epigenetic regulators, such as RNF2, directly and functionally control powerful gene networks that are vital in multiple cancer processes. and top layer 0.5%) mixed with DMEM growth medium and fetal bovine serum were prepared. Two thousand cells were mixed in the top agar layer during plating and colony formation was monitored. Upon appropriate size of colonies, the colonies were stained with p-iodonitro tetrazolium violet, pictures taken and counted manually or with ImageJ software. Boyden chamber matrigel invasion assay was performed as described earlier (3). Briefly, chambers were brought to room chamber and hydrated in serum free media.
One hundred thousand cells were seeded inside the chamber in serum-free media and assayed for ability to move to the bottom of the chamber in response to 10% serum containing media present in the well after 24-48 hrs.
Mice injections and tumor studies
Four to six weeks old NCR-NUDE mice were purchased from Taconic and injected intradermally with 1 million cells. Tumor volume was measured at designated time 
Tissue Microarray and immunohistochemistry
Tissue microarray for melanoma progression has been previously described (28). RNF2 immunohistochemistry was performed using Prestige rabbit polyclonal antibody (Sigma).
TMA slides were heated at 65 o C for 1hr, deparaffinized in xylene, and rehydrated. 
Chromatin Immunoprecipitation and next-generation sequencing (ChIP-Sequencing)
Chromatin immunoprecipitation was performed as described earlier (29). Library preparation was done using NEB reagents as described earlier (29). Sequencing was performed in Hiseq2000 (Illumina). Data analysis was performed as described in the Supplementary Methods.
RNA isolation, quantitative PCR and Microarray
RNA was isolated using RNeasy Kit (Qiagen) per manufacturer's instructions. cDNA was prepared using SuperScript III (Life Technologies) using manufacturer's instructions.
Research. Microarray experiments were performed in MD Anderson Center for ncRNA Sequencing core facility. Microarray data was analyzed using LIMMA bioconductor package. Details of analysis are in Supplementary Methods. All genomic data sets are publicly available at NCBI's GEO database (GSE51928, GSE51929 and GSE51930).
Survival analysis in TCGA data
TCGA melanoma data (2013_04_06 stddata run) were retrieved from Genome Data Analysis Center of TCGA. Survival intervals from date of specimen submission to patients' death/last follow-up were available in 154 cases. Statistical significance of survival differences was estimated by Kaplan-Meier curves and log rank test in R.
Protein isolation and Western blotting
Proteins were made using RIPA buffer (Boston BioProducts) and complete mini protease inhibitor cocktail (Roche). Western blotting was performed by standard procedure using Invitrogen or Bio-Rad precast 4-12% gels. Antibodies used were anti-V5 (Invitrogen), anti-vinculin (Sigma), anti-H2AK119ub (Millipore), anti-RNF2 (Sigma), anti-ID1 (SCBT), anti-ID2 (SCBT), anti-ID3 (SCBT). Secondary antibodies used were from LICOR. Blots were developed using LICOR Odyssey imager.
Mouse Models
Generation and characterization of iBIP mice and RNF2 L/L mice are described in Supplementary Methods.
ChromHMM Analysis
Research. (shCCND2-1 and shCCND2-2). Across all panels "*" denotes significant change t-test p < 0.05 and "**" represents p value <0.01.
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